Reveal the association between acute myeloid leukemia mutations and drugs

According to a cancer study published online by the British journal Nature on the 17th, the Oregon Health and Science University has published a dataset that reveals specific mutations and drug susceptibility in patients with acute myeloid leukemia (AML) that have not been previously discovered. The relationship between. These findings will enhance the understanding of the biological and clinical aspects of acute myeloid leukemia.

Acute myeloid leukemia is a very diverse disease , and at least 11 genetic classes and nearly 2,000 different mutant genes have been observed in patients. These complex mutation patterns make it challenging to develop effective drug therapies, and although there are currently a few available therapies, they have remained largely unchanged over the past 30 to 40 years.

Oregon Health and Science University researcher Brian Duke and colleagues reported the preliminary results of the project called "Beat AML." The "Beat AML" project is a data set of 672 tumor biopsies containing 562 AML patients. The team used a combination of exome sequencing (sequencing genes encoding proteins), RNA sequencing, and drug sensitivity analysis to study differences in tumor samples. They found new mutations that were not previously observed in AML, and the association between mutations and drug treatment responses. For example, a significant association between FLT3, NPM1, and DNMT3A gene mutations and ibrutinib drug sensitivity was observed, suggesting that patients carrying a mutant version of these genes (particularly FLT3) may be more sensitive to this particular therapy.

The researchers said that these results, combined with other findings based on the dataset in the future, will bring new clinical approaches to the treatment of AML to the medical community. (Reporter Zhang Mengran)